MedTrace Logo

Drug Utilization Study for Olodaterol

NCT03030638 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 27606

Last updated 2019-06-27

Study results available
· View outcomes & findings →

Summary

This study aims to characterise the use of single-agent olodaterol and single-agent indacaterol, the only marketed long-acting beta2-agonist (LABA)s authorised for chronic obstructive pulmonary disease (COPD), but not for asthma, in clinical practice.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Olodaterol

Drug

DRUG

Indacaterol

Drug

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Eligibility

Min Age
28 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-08
Primary Completion
2018-03-31
Completion
2018-03-31

Countries

  • Denmark
  • France
  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03030638 on ClinicalTrials.gov